CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
261
30
345
520
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
31,839
68,291
49,053
19,455
Selling General and Administrative
17,345
14,684
9,700
6,263
Total Operating Expenses
49,184
82,975
58,753
25,718
Operating Income or Loss
-48,923
-82,945
-58,408
-25,198
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-389
127
-567
-684
Income Before Tax
-49,312
-82,818
-58,975
-25,882
Income Tax Expense
-
-
-
-
Income from Continuing Operations
-49,312
-82,818
-58,975
-25,882
Net Income
-49,312
-82,818
-58,975
-25,882
Net Income available to common shareholders
-49,312
-82,818
-58,975
-25,882
Reported EPS
Basic
-
-2.69
-2.33
-1.97
Diluted
-
-2.69
-2.33
-1.97
Weighted average shares outstanding
Basic
-
30,734
25,312
13,111
Diluted
-
30,734
25,312
13,111
EBITDA
-
-82,756
-58,226
-25,133